Advocate Clinical Laboratories
Every Sample is a Life™

Test Bulletin

August 2026

Update Regarding Acceptable Containers for Cyclospora/Cystoisospora Screen (Test Order Code LAB9025) and Ova and Parasite Exam, Fecal (Immunocompromised or Travel History) (Test Order Code LAB11409)

Due to a widespread backorder of EcoFix preservative, alternative specimen collection containers have been identified for impacted tests. Updates have been made to the following assays:

Test	Test Order Code	Container Update	Container Photo
Cyclospora/ Cystoisospora Screen	**LAB9025**	SAF fixative is an acceptable container type and has been added as a container type in Epic	
Ova and Parasite Exam, Fecal (Immunocompromised or Travel History)	**LAB11409**	Zn-PVA fixative is an acceptable container type and has been added as a container type in Epic	

Note: Each assay has differing alternative preservative containers, which are *not* interchangeable. Zn-PVA is not acceptable for Cyclospora/Cystoisospora Screen (Test Order Code LAB9025) and SAF is *not* acceptable for Ova and Parasite Exam, Fecal (Test Order Code LAB11409).

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 8/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2608a

ACL Offers Genomic Variant Reporting for Myeloproliferative Neoplasm Panel (MPN) (Test Order Code LAB12257)

Effective Wednesday, August 19, 2026, ACL Laboratories will offer genomic variant reporting for all genes included in the Myeloproliferative Neoplasm Panel (MPN) (Test Order Code LAB12257).

Clinical indication

This assay covers the most common mutations identified in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This panel covers exons 12-15 of *JAK2*, exon 9 of *CALR*, and exon 10 of *MPL* genes which will now also report the specific mutation identified rather than just a detected/not detected result. These specific mutations will be discretely reported in EPIC and will look similar to other NGS tests performed at ACL.

Test Method

- Next Generation Sequencing

Specimen Requirements

- Blood: One lavender (K2EDTA) 3.0 mL OR One pink (K2EDTA) 6.0 mL
- Bone marrow: One lavender (K2EDTA) 3.0 mL

Stability & Transport

- Ambient: 3 days, Refrigerated: 2 weeks, Frozen: Unacceptable

Unacceptable Conditions

- Decalcified
- Plasma or serum specimens
- Recent blood transfusions
- FFPE tissue blocks/slides or fresh or frozen tissue
- Clotted specimens
- Hemolyzed specimens, dependent on the level of hemolysis

Testing Schedule & Reporting

- Performed: Weekdays
- Performing Site: Illinois Central Laboratory – Molecular Pathology
- Reporting Time: Final results within 14 days

If you have any questions, please contact: ACL Molecular Pathology Laboratory at Rosemont (847.349.7182) or ACL Client Services (800.877.7016)

ACL Laboratories Discontinues 2019 Novel Coronavirus (SARS-CoV-2) PCR (Test Order Code LAB10635)

Effective Wednesday, August 19, 2026, ACL Laboratories will discontinue 2019 Novel Coronavirus (SARS-CoV-2) PCR (Test Order Code LAB10635). An acceptable alternative test is currently offered by ACL Laboratories -- Rapid SARS-CoV-2 by PCR (Test Order Code LAB10644).

Specimen collection requirements for Rapid SARS-CoV-2 by PCR are nasal, mid-turbinate or nasopharyngeal swab submitted in Universal Transport Media (UTM).

Rapid SARS-CoV-2 by PCR is currently performed by all ACL Illinois and Wisconsin Rapid Response Laboratories and ACL's Wisconsin Central Laboratory.

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 8/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2608a

New Orderable Code: Adenosine Deaminase in Pericardial Fluid

Effective Wednesday, August 19, 2026, Adenosine Deaminase in Pericardial Fluid (Test Order Code LAB13504) will be available as an orderable test.

Test	Container Update
Test Order Code	LAB13504
Specimen Requirement	Pericardial Fluid
Collection Tube	Sterile Tube
Temperature	Frozen
Stability	30 days
Methodology	Quantitative Spectrophotometry
TAT	Final within 6 days
Performing Laboratory	ARUP

New Orderable Code: Anti-sp100 and Anti-gp210 Antibodies, IgG

Effective Wednesday, August 19, 2026, Anti-sp100 and Anti-gp210 Antibodies, IgG (Test Order Code LAB13500) will be available as an orderable test.

Test	Container Update
Test Order Code	LAB13500
Specimen Requirement	1.0 mL (minimum 0.3 mL) Serum
Collection Tube	Gold Gel
Temperature	Refrigerated
Stability	2 weeks
Methodology	Semi-Quantitative Enzyme-Linked Immunosorbent Assay
TAT	Final within 10 days
Performing Laboratory	ARUP

Effective Wednesday, August 19, 2026, the following send out assays will be updated.

Vitamin B3 (Niacin and Metabolites)

	Current (Deactivated 8.19.2026)	Replacement (Activated 8.19.2026)
Test Name	Vitamin B3 (Niacin and Metabolites), Serum/Plasma	Vitamin B3 (Niacin and Metabolites), Serum/Plasma
Test Order Code	LAB11939	LAB13555
Performing Lab	ARUP	ARUP
Specimen Type	Serum or Plasma	1 mL (minimum 0.3 mL) Serum or Plasma
Collection Container	Plain Red or Lavender	Gold Gel Also acceptable: Plain Red, or Green Lithium Heparin, or Green Sodium Heparin
Temperature	Frozen	Frozen
Stability	1 month	1 month
Methodology	Quant Liquid Chromatography - Tandem Mass Spec	Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
TAT	Final within 11 days	Final within 7 days

Porphyrins, Fractionated Urine (Test Order Code LAB9772)

Shipping and Handling Instructions Update: Critical Protect from Light

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 8/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2608a

ACL Updates Pathology Smear Review

ACL will implement a change to Pathology Smear Review testing (Test Order Code LAB10565) for Illinois and Wisconsin divisions, in alignment with ordering practices in the Southeast divisions. **Effective Thursday, August 20, 2026,** only pathologists, oncology providers, and laboratory staff will be authorized to order a Pathology Smear Review for patients. Contact the performing lab with any questions. Providers will be able to consult with pathologists to review patient cases and determine whether a Pathology Smear Review is necessary for optimal patient care.

The criteria for determining when a pathologist smear review is required and automatically ordered are below. Please note: Smears are performed on the first occurrence of meeting the criteria only.

1. Peripheral Blood Review Criteria:
    a. Platelet counts <50,000/µL with schistocytes present
    b. WBC >50,000/µL
    c. Any patient with suspected blasts, suspected re-emergence of blasts, or any unidentified/abnormal mononuclear cells (including suspected lymphoma cells)
    d. Reactive lymphocyte count >15% (not required if MONO test is positive)
    e. Lymphocytosis with patient >50 years of age and >5,000 absolute lymphocyte count
    f. Prolymphocytes >10% g. Hypo-segmented PMNs suggestive of Pelger-Huet anomaly or dysplastic pelgeroid changes
    g. Dysplastic NRBC (i.e., bi-nucleated, nuclear blebs)
    h. Unidentified RBC inclusions or suspected parasites

Cited articles that support this change:

Beckman, A.K. et al. (2020) *Clinician-ordered peripheral blood smears have low reimbursement and variable clinical value: a three-institution study, with suggestions for operational efficiency.*

Kaur, P. (2023) *Hematology lab waste reduction through implementation of peripheral smear review criteria, wileyonlinelibrary.com/journal/ijlh.*

Kurt-Mangold, M.E. et al. (2018) *Clinical Utility of Ordered Pathology Blood Smear Reviews - an Overused Resource? .*

Lollie, T.K. et al. (2022) *Educational cost-effective intervention to reduce pathologist's peripheral blood smears reviews with non-contributory findings: an academic institution experience.*

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

Created: 8/2026 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2608a